LIVER FIBROSIS: PATHOGENESIS, PREVENTION AND TREATMENT

REFERENCES

1. Schuppan D, Gressner AM. Metabolism of collagen and other extracellular proteins. In: Oxford Textbook of Clinical Hepatology (Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J, eds), 1998, Oxford University Press, Oxford, pp. 381-408.

2. Olaso E, Friedman SL. Molecular regulation of hepatic fibrosis. J Hepatol 1998; 29: 836-847.

3. Gressner AM, Schuppan D. Pathophysiology of liver fibrosis. In: Oxford Textbook of Clinical Hepatology (Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J, eds), 1998, Oxford University Press, Oxford, pp. 607-628.

4. Knittel T, Kobold D, Saile B, Grundmann A, Neubauer K, Piscaglia F, Ramadori G. Rat liver myofibroblasts and hepatic stellate cells: Different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 1999; 117: 1205-1221.

5. Schuppan D, Strobel D, Hahn EG. Hepatic fibrosis - therapeutic strategies. Digestion 1998; 59: 385-390.

6. Cho JJ, Hocher B, Herbst H, Jia JJ, Boigk G, Hahn EG, Riecken EO, Schuppan D. An oral endothelin A receptor antagonist blocks collagen synthesis and deposition in advanced rat secondary fibrosis. Gastroenterology, in press.

7. Boigk G, Stroedter L, Herbst H, Waldschmidt, Riecken EO, Schuppan D. Silymarin retards hepatic collagen accumulation in early and advanced biliary fibrosis secondary to bile duct obliteration in the rat. Hepatology 1997; 26: 643-649.

8. Sobesky R, Maturin P, Charlotte F, Mousalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T. Modelling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C. Gastroenterology 1999; 116: 378-386.

9. Schiffman M, Hoffmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, Ferreira-Gonzales A, Mills AS, Garret C. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C and persistent viremia. Gastroenterology 1999; 117: 1164-1172.

10. Raetsch C, Boigk G, Stroeter L, Waldschmidt J, Herbst H, Riecken EO, Schuppan D. Pentoxifyllin inhibits hepatic collagen deposition in early but not advanced rat biliary fibrosis. Gastroenterology 1996; 110: A1301 (abstract).

11. Huang SS, Liu Q, Johnson FE, Konish Y, Huang JS. Transforming growth factor beta peptide antagonists and their conversion to partial agonists. J Biol Chem 1997; 272: 27155-27159.

12. Komesli S, Vivien D, Dutartre P. Chimeric extracellular domains type II transforming growth factor (TGF)-beta receptor fused to the Fc region of human immunoglobulin as a TGF-beta antagonist. Eur J Biochem 1998; 254: 505-513.

13. Paradis V, Dargere D, Vidaud M, De Gouville AC, Huet S, Martinez V, Gauthier JM, Ba N, Sobesky R, Ratziu V, Bedossa P. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999; 30: 968-976.

14. Zhu J, Wu J, Frizell E, Liu SL, Bashey R, Rubin R, Norton P, Zern MA. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999; 117: 1198-1204.

15. Grinnell F. Fibroblasts, myofibroblasts and wound contraction. J Cell Biol 1994; 124: 401-404.

16. Atkinson J, Ruehl M, Becker J, Ackermann R, Schuppan D. Collagen VI regulates normal and transformed mesenchymal cell proliferation in vitro. Exp Cell Res 1996; 228: 283-291.

17. Ruehl M, Johannsen M, Atkinson J, Manski D, Sahin E, Schuppan D (1999). Soluble collagen VI induces tyrosine-phosphorylation of paxillin and focal adhesion kinase and activates the MAP-kinase erk2 in fibroblasts. Exp Cell Res 1999; 250: 548-557.

18. Ruehl M, Sahin E, Johannsen M, Strefeld T, Riecken EO, Schuppan D. Soluble collagen VI drives serum starved fibroblasts through S-phase and prevents apoptosis via downregulation of BAX. J Biol Chem 1999; 274: 34361-34368.

19. Beljaars L, Molema G, Weert B, Bonnema H, Olinga P, Groothius GM, Meijer DK, Poelstra K. Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 1999; 29: 1486-1493.

20. Beljaars L, Molema G, Schuppan D, Geerts A, deBleser P, Weert B, Meijer DKF, Poelstra K. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J Biol Chem, in press.

21. Beljaars L, Poelstra K, Weert B, Molema G, Schuppan D, Meijer DKF. The development of novel albumin carriers to hepatic stellate cells by application of cyclopeptide moieties recognizing collagentype VI and platelet derived growth factor. Hepatology 1998; 28: 313A (abstract).

22. Schuppan D, Stölzel U, Oesterling C, Somasundaram R. Serum markers for liver fibrosis. J Hepatol 1995; 22 (S2): 82-88.

Regresar al Artículo

Regresar